OPGN - OpGen, Inc.
NASDAQ
->
Healthcare
->
Diagnostics & Research
Rockville,
United States
Type: Equity
OPGN price evolution
OPGN
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $10.28 | $16.59 | $30.65 | $36.08 |
| Short term investments | ||||
| Net receivables | $0.67 | $0.74 | $0.27 | $1.17 |
| Inventory | $3.39 | $4.69 | $4.81 | $4.71 |
| Total current assets | $13.39 | $20.21 | $33.49 | $39.74 |
| Long term investments | ||||
| Property, plant & equipment | $4.53 | $4.81 | $5.48 | $5.92 |
| Goodwill & intangible assets | $12 | $19.85 | $21.37 | $21.98 |
| Total noncurrent assets | $19.57 | $28.6 | $30.77 | $31.92 |
| Total investments | ||||
| Total assets | $32.96 | $48.81 | $64.26 | $71.67 |
| Current liabilities | ||||
| Accounts payable | $0.68 | $0.73 | $0.87 | $1.31 |
| Deferred revenue | $0.19 | |||
| Short long term debt | $8.7 | $11.3 | $14.87 | $15.02 |
| Total current liabilities | $12.01 | $14.39 | $19.01 | $19.92 |
| Long term debt | $6.74 | $6.75 | $10.82 | $10.16 |
| Total noncurrent liabilities | $7.01 | $7.05 | $11.08 | $10.53 |
| Total debt | $15.44 | $18.05 | $25.69 | $25.18 |
| Total liabilities | $19.02 | $21.45 | $30.09 | $30.45 |
| Shareholders' equity | ||||
| Retained earnings | -$262.29 | -$248.19 | -$242.35 | -$235.54 |
| Other shareholder equity | -$1.66 | -$1.13 | $0.1 | $0.59 |
| Total shareholder equity | $13.94 | $27.36 | $34.17 | $41.22 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $36.08 | $13.36 | $2.71 | $4.57 |
| Short term investments | $2.52 | |||
| Net receivables | $1.17 | $0.65 | $0.57 | $0.37 |
| Inventory | $4.71 | $3.17 | $0.47 | $0.54 |
| Total current assets | $39.74 | $16.89 | $6.67 | $5.78 |
| Long term investments | ||||
| Property, plant & equipment | $5.92 | $5.79 | $2.13 | $1.22 |
| Goodwill & intangible assets | $21.98 | $24.61 | $1.42 | $1.69 |
| Total noncurrent assets | $31.92 | $32.86 | $3.75 | $3.17 |
| Total investments | $2.52 | |||
| Total assets | $71.67 | $49.75 | $10.42 | $8.95 |
| Current liabilities | ||||
| Accounts payable | $1.31 | $1.87 | $1.06 | $1.62 |
| Deferred revenue | $0.01 | $0.01 | $0.02 | |
| Short long term debt | $15.02 | $1.93 | $1.97 | $0.8 |
| Total current liabilities | $19.92 | $7.37 | $4.94 | $4.38 |
| Long term debt | $10.16 | $20.92 | $1.19 | $1.1 |
| Total noncurrent liabilities | $10.53 | $21.19 | $1.19 | $1.26 |
| Total debt | $25.18 | $22.85 | $3.16 | $1.9 |
| Total liabilities | $30.45 | $28.56 | $6.13 | $5.64 |
| Shareholders' equity | ||||
| Retained earnings | -$235.54 | -$200.74 | -$174.52 | -$162.08 |
| Other shareholder equity | $0.59 | $2.55 | -$0.02 | -$0.01 |
| Total shareholder equity | $41.22 | $21.19 | $4.29 | $3.31 |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.45 | $0.97 | $0.47 | $1.43 |
| Cost of revenue | $1.9 | $0.66 | $0.32 | $0.86 |
| Gross Profit | -$1.45 | $0.31 | $0.15 | $0.57 |
| Operating activities | ||||
| Research & development | $2.03 | $2.27 | $2.32 | $2.86 |
| Selling, general & administrative | $3.05 | $3.3 | $3.68 | $3.5 |
| Total operating expenses | $12.06 | $5.58 | $5.99 | $6.36 |
| Operating income | -$13.51 | -$5.27 | -$5.85 | -$5.79 |
| Income from continuing operations | ||||
| EBIT | -$13.53 | -$5.06 | -$5.53 | -$5.55 |
| Income tax expense | $0.04 | |||
| Interest expense | $0.57 | $0.78 | $1.27 | $1.21 |
| Net income | ||||
| Net income | -$14.1 | -$5.84 | -$6.8 | -$6.81 |
| Income (for common shares) | -$14.1 | -$5.84 | -$6.8 | -$13.98 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4.31 | $4.21 | $3.5 | $2.95 |
| Cost of revenue | $2.85 | $3.85 | $1.63 | $1.85 |
| Gross Profit | $1.46 | $0.37 | $1.87 | $1.1 |
| Operating activities | ||||
| Research & development | $10.91 | $9.96 | $5.12 | $5.68 |
| Selling, general & administrative | $13.65 | $11.9 | $7.72 | $8.6 |
| Total operating expenses | $24.73 | $23.08 | $14.14 | $14.28 |
| Operating income | -$23.27 | -$22.72 | -$12.27 | -$13.18 |
| Income from continuing operations | ||||
| EBIT | -$29.96 | -$22.68 | -$12.26 | -$13.18 |
| Income tax expense | $0.04 | $0.13 | ||
| Interest expense | $4.8 | $3.4 | $0.19 | $0.19 |
| Net income | ||||
| Net income | -$34.81 | -$26.21 | -$12.45 | -$13.37 |
| Income (for common shares) | -$41.97 | -$26.21 | -$12.45 | -$13.37 |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$14.1 | -$5.84 | -$6.8 | -$6.81 |
| Operating activities | ||||
| Depreciation | $0.33 | $0.46 | $0.51 | $0.61 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.23 | $0.26 | $0.24 | $0.21 |
| Total cash flows from operations | -$4.75 | -$6.66 | -$5.04 | -$3.79 |
| Investing activities | ||||
| Capital expenditures | -$0.1 | -$0.04 | -$0.04 | -$0.16 |
| Investments | ||||
| Total cash flows from investing | -$0.1 | -$0.04 | -$0.04 | -$0.16 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.99 | $1.48 | ||
| Net borrowings | -$1.89 | -$6.83 | -$0.02 | -$0.03 |
| Total cash flows from financing | -$0.9 | -$6.83 | -$0.02 | $15.41 |
| Effect of exchange rate | -$0.58 | -$0.56 | -$0.41 | -$0.74 |
| Change in cash and equivalents | -$6.33 | -$14.09 | -$5.51 | $10.73 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$34.81 | -$26.21 | -$12.45 | -$13.37 |
| Operating activities | ||||
| Depreciation | $2.71 | $2.33 | $0.92 | $0.73 |
| Business acquisitions & disposals | $1.27 | |||
| Stock-based compensation | $0.88 | $0.32 | $0.37 | $0.86 |
| Total cash flows from operations | -$21.48 | -$23.4 | -$11.51 | -$11.07 |
| Investing activities | ||||
| Capital expenditures | -$1.98 | -$0.13 | -$0 | -$0.14 |
| Investments | -$2.2 | -$2.5 | ||
| Total cash flows from investing | -$1.98 | -$1.06 | -$2.5 | -$0.14 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $34.31 | $33.79 | $13.06 | $14.13 |
| Net borrowings | -$0.71 | $0.29 | -$0.89 | -$0.28 |
| Total cash flows from financing | $47.45 | $34.09 | $12.17 | $13.85 |
| Effect of exchange rate | -$1.46 | $1.59 | -$0 | $0.01 |
| Change in cash and equivalents | $22.52 | $11.21 | -$1.84 | $2.65 |
News
|
Penny Stock OpGen Surges After UTI Panel Test Meets Primary Goal In Clinical Trial
Benzinga via Yahoo Finance
14 Dec 2022
|
|
Analysts’ New Coverage for June 2nd (ABIO, ACU, AHPI, CALT, CNTB, CRAYF, CREX, EVFM, GALT, GLYC)
ETF DAILY NEWS
2 Jun 2022
|
|
Analysts’ Upgrades for June 1st (BME, BMRRY, BPMC, DHR, DLTR, DMRC, FINV, FMX, GCHEF, HBCP)
ETF DAILY NEWS
1 Jun 2022
|
|
Research Analysts’ Price Target Changes for May 31st (AFLYY, BHP, BTI, BURBY, CBWBF, CGC, CNVVY,...
ETF DAILY NEWS
31 May 2022
|
|
OpGen, Inc. (OPGN) Reports Q1 Loss, Lags Revenue Estimates
Zacks via Yahoo Finance
13 May 2022
|
|
Equities Research Analysts’ New Coverage for May 9th (ADXS, AHPI, AIRC, ANGPY, APLD, BRBR, CRM,...
ETF DAILY NEWS
9 May 2022
|
|
68 Biggest Movers From Yesterday
Benzinga
19 Apr 2022
|
|
21 Stocks Moving in Wednesday's Pre-Market Session
Benzinga
6 Apr 2022
|
|
35 Stocks Moving In Wednesday's Mid-Day Session
Benzinga
31 Mar 2022
|
|
24 Stocks Moving in Wednesday's Pre-Market Session
Benzinga
30 Mar 2022
|
Fundamentals
| Market cap | $72.02M |
|---|---|
| Enterprise value | $77.19M |
| Shares outstanding | 48.34M |
| Revenue | $3.31M |
|---|---|
| EBITDA | -$27.77M |
| EBIT | -$29.68M |
| Net Income | -$33.56M |
| Revenue Q/Q | -63.79% |
| Revenue Y/Y | -21.77% |
| P/E ratio | -2.15 |
|---|---|
| EV/Sales | 23.31 |
| EV/EBITDA | -2.78 |
| EV/EBIT | -2.60 |
| P/S ratio | 21.75 |
| P/B ratio | 4.62 |
| Book/Share | 0.32 |
| Cash/Share | 0.21 |
| EPS | -$0.69 |
|---|---|
| ROA | -61.66% |
| ROE | -115.04% |
| Debt/Equity | 0.74 |
|---|---|
| Net debt/EBITDA | -0.31 |
| Current ratio | 1.11 |
| Quick ratio | 0.83 |